Overview

Long Term Extension Trial of Setmelanotide

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in patients who have completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Rhythm Pharmaceuticals, Inc.
Treatments:
alpha-MSH